Last updated: October 7, 2023
Sponsor: University of Manitoba
Overall Status: Active - Not Recruiting
Phase
4
Condition
Chronic Musculoskeletal Pain
Treatment
Intraarticular Knee Placebo
6% aqueous phenol
MethylPREDNISolone 40 MG
Clinical Study ID
NCT06000709
HS25899
Ages 40-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Severe knee pain for more than 6 months, defined as Numeric rating scale (NRS) scoreof 6 and greater, unresponsive to conservative medical treatment
- Radiological OA grade 2 to 4 (Kellgren-Lawrence scale)
Exclusion
Exclusion Criteria:
- Previous total knee replacement on the index knee
- Prior knee radiofrequency ablation on the index knee
- Connective tissue diseases with knee involvement (e.g. rheumatoid arthritis)
- Body mass index ≥ 40 kg/m2
- Uncontrolled coagulopathy, defined as supratherapeutic dose of anticoagulationmedication
- Allergy to local anesthetics
- Unstable opioid consumption, defined as an increase >10% in dosage during the last 3months prior to recruitment.
Study Design
Total Participants: 40
Treatment Group(s): 4
Primary Treatment: Intraarticular Knee Placebo
Phase: 4
Study Start date:
October 20, 2023
Estimated Completion Date:
July 31, 2024